Abstract
Gout has been recognized for centuries and is currently the most common inflammatory arthritis in men, affecting approximately eight million adults in the United States (Zhu et al. Arthritis Rheum 63(10):3136–41, 2011). Gout is a multifactorial disease characterized by hyperuricemia and monosodium urate monohydrate crystal deposition in the joint and soft tissue. Classically, gout presents as recurrent, acute, monoarticular, or oligoarticular arthritis. The prevalence of gout has increased markedly in the United States in the last two decades due to increased prevalence of associated co-morbidities and longevity. Several new treatments for both acute and chronic gout have been developed in the past decade and they will be reviewed in this chapter using two challenging gout cases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med. 1964;36:561–70.
Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science. 1967;155(3770):1682–4.
Lens XM, Banet JF, Outeda P, et al. A novel pattern of mutation in uromodulin disorders: autosomal dominal medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy, and autosomal dominant glomerulocystic kidney disease. Am J Kidney Dis. 2005;46(1):52–7.
Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36:1041–8.
Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48(5):582–6.
Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare. Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8.
Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–20.
So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
Chen K, Fields T, Mancuso CA, et al. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40(3):210–4.
So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gout arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:2845–9.
Schlesinger N, Mysler E, Meulemeester M, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis. 2011;70:1264–71.
Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jetanalin, P., Lee, S.J. (2013). Gout. In: Mahmoudi, M. (eds) Challenging Cases in Rheumatology and Diseases of the Immune System. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5088-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5088-7_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5087-0
Online ISBN: 978-1-4614-5088-7
eBook Packages: MedicineMedicine (R0)